DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,122 filers reported holding DANAHER CORPORATION in Q2 2024. The put-call ratio across all filers is 1.04 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,639,879 | -8.8% | 10,566 | -8.8% | 0.31% | -7.7% |
| Q1 2024 | $2,893,227 | +8.5% | 11,586 | +0.5% | 0.34% | 0.0% |
| Q4 2023 | $2,665,985 | +4.5% | 11,524 | +12.1% | 0.34% | -6.6% |
| Q3 2023 | $2,550,535 | +37.0% | 10,280 | +32.6% | 0.36% | +44.4% |
| Q2 2023 | $1,861,262 | -56.3% | 7,755 | -54.1% | 0.25% | -58.8% |
| Q1 2023 | $4,255,237 | +3.2% | 16,883 | +8.6% | 0.61% | -6.9% |
| Q4 2022 | $4,124,682 | +4.3% | 15,540 | +1.1% | 0.65% | +64.2% |
| Q3 2022 | $3,955,378 | +9.2% | 15,372 | +7.2% | 0.40% | +10.9% |
| Q2 2022 | $3,620,751 | +8.6% | 14,337 | +26.1% | 0.36% | -25.6% |
| Q1 2022 | $3,334,318 | -7.8% | 11,367 | +3.4% | 0.48% | -0.8% |
| Q4 2021 | $3,617,795 | +93.7% | 10,996 | +79.2% | 0.48% | +75.7% |
| Q3 2021 | $1,868,072 | -10.1% | 6,136 | -20.7% | 0.28% | -11.0% |
| Q2 2021 | $2,077,604 | +22.0% | 7,742 | +2.3% | 0.31% | +9.9% |
| Q1 2021 | $1,702,957 | +4.5% | 7,566 | +3.2% | 0.28% | -4.7% |
| Q4 2020 | $1,628,966 | – | 7,333 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
| Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
| Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
| Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
| ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
| CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
| Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
| Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
| BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
| Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |